ICLRICON Public Limited Company

$158.47

$80.0852 weeks$202.92

Price

$158.47-11%1Y

1M-1.7%1Y-11%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Lagging

1/10

Value11

Quality56

Momentum23

Growth20

Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. We offer a full range of clinical, consulting and commercial services that range from clinical development strategy, planning and trial design, to full study execution, and post-market commercialization. ICON provides its services across a range of clinical outsourcing operating models including strategic partnerships, preferred provider, full-service delivery to functional service provision and stand-alone services.

In the company’s own words · 20-F filed May 27, 2026 · SEC EDGAR

P/E (TTM)74.0

Market Cap$12.33B

1Y Return-11%

5Y Return-33%

ICON Public Limited Company (ICLR) reported revenue of $2.03B in Q1 2026 (quarter ended Mar 31, 2026), up 0.9% from the same quarter a year earlier. That came with a gross margin of 23% and net income of $105M (5.2% of revenue). For the full year FY2025, revenue was $8.25B (+0.8% year on year) and net income $229M.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Diagnostics & Research

Ranks #17 of 17 by Smart Score

Compare peers

MEDP-0.12%

Medpace Holdings, Inc.

QGEN-2.5%

Qiagen N.V.

GH-0.31%

Guardant Health, Inc.

TWST+2.5%

Twist Bioscience Corporation